Sagimet Biosciences Starts Phase III Acne Drug Trial

The company has dosed the first patient in a U.S. clinical study for denifanstat to treat moderate to severe acne.

Updated on Oct. 23, 2026 in Beauty

Sagimet Biosciences Starts Phase III Acne Drug Trial

Live Poll

Do you believe new medical clinical trials are effectively addressing unmet needs for common skin conditions?

Sagimet Biosciences has officially launched its Phase III AURORA clinical trial for denifanstat, a fatty acid synthase inhibitor. This U.S. study marks a key step in testing the treatment for adults and adolescents aged 12 and older with moderate to severe acne.

Why it matters

The trial aims to provide data to support a future New Drug Application submission in the U.S. market. It addresses a treatment need for approximately 10 million Americans currently suffering from moderate to severe forms of the condition.

The clinical study aims to enroll approximately 800 patients across the United States. This population segment represents a significant portion of the roughly 10 million Americans who struggle with moderate to severe acne.

The players

Sagimet Biosciences

This is a clinical-stage biopharmaceutical company focused on developing therapies for diseases related to fatty acid synthase inhibition.

Ascletis Pharma

Based in Hong Kong, this biotechnology company focuses on research and development for treatments in viral, liver, and dermatological diseases.

The details

Denifanstat acts as a fatty acid synthase inhibitor to target acne symptoms. Ascletis maintains exclusive rights to develop and commercialize the drug in Greater China, where it previously performed a 12-week Phase III trial.

October 23, 2026: Ascletis announced that the first patient was dosed in the AURORA trial.

Culture Shift

The AURORA clinical trial marks a significant evolution in dermatological research by testing a novel fatty acid synthase inhibitor. This study reflects a broader move within the medical community toward developing targeted inhibitors to improve outcomes for adolescent and adult skin health.

While this study is currently in the clinical trial phase, participants may eventually gain access to a new treatment option for chronic skin conditions. The trial results will dictate if this drug becomes a future alternative to existing prescription routines for acne management.

The takeaway

This trial highlights the ongoing effort to introduce specialized fatty acid inhibitors into the dermatological market. Patients should continue working with their healthcare providers to manage acne while awaiting future regulatory updates.